# Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease

> **NCT05031806** · PHASE1 · COMPLETED · sponsor: **Xequel Bio, Inc.** · enrollment: 30 (actual)

## Conditions studied

- Dry Eye Disease

## Interventions

- **DRUG:** iNexin™ (0.08% aCT1)
- **DRUG:** iNexin™ (0.4% aCT1)
- **DRUG:** iNexin™ (2.0% aCT1)
- **DRUG:** Vehicle (eye drop formulation without aCT1)

## Key facts

- **NCT ID:** NCT05031806
- **Lead sponsor:** Xequel Bio, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05031806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05031806, "Evaluation of the Safety, Tolerability and Efficacy of iNexin™ for the Treatment of the Signs and Symptoms Associated With Dry Eye Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05031806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*